|
1
|
Rouprêt M, Babjuk M, Compérat E, Zigeuner
R, Sylvester R, Burger M, Cowan N, Böhle A, Van Rhijn BW, Kaasinen
E, et al: European guidelines on upper tract urothelial carcinomas:
2013 update. Eur Urol. 63:1059–1071. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Kauffman EC and Raman JD: Bladder cancer
following upper tract urothelial carcinoma. Expert Rev Anticancer
Ther. 8:75–85. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ku JH, Choi WS, Kwak C and Kim HH: Bladder
cancer after nephroureterectomy in patients with urothelial
carcinoma of the upper urinary tract. Urol Oncol. 29:383–387. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Liu YQ, Lu J, Zhao L, Hou XF and Ma LL:
Prognostic factors for intravesical recurrence after surgery for
upper tract urothelial carcinoma in renal transplant recipients.
Beijing Da Xue Xue Bao. 47:605–610. 2015.(In Chinese). PubMed/NCBI
|
|
6
|
Rouprêt M, Babjuk M, Compêrat E, Zigeuner
R, Sylvester RJ, Burger M, Cowan NC, Böhle A, Van Rhijn BW,
Kaasinen E, et al: European association of urology guidelines on
upper urinary tract urothelial cell carcinoma: 2015 Update. Eur
Urol. 68:868–879. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Yamashita S, Ito A, Mitsuzuka K, Tochigi
T, Namima T, Soma F, Aizawa M, Ioritani N, Kaiho Y and Arai Y:
Clinical implications of intravesical recurrence after radical
nephroureterectomy for upper urinary tract urothelial carcinoma.
Int J Urol. 23:378–384. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kulis M and Esteller M: DNA methylation
and cancer. Adv Genet. 70:27–56. 2010.PubMed/NCBI
|
|
9
|
Mikeska T, Bock C, Do H and Dobrovic A:
DNA methylation biomarkers in cancer: Progress towards clinical
implementation. Expert Rev Mol Diagn. 12:473–487. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Andres G, Ashour N, Sanchez-Chapado M,
Ropero S and Angulo JC: The study of DNA methylation in urological
cancer: Present and future. Actas Urol Esp. 37:368–375. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Xiong G, Liu J, Tang Q, Fan Y, Fang D,
Yang K, Xie F, Zhang M, Zhang L, Liu L, et al: Prognostic and
predictive value of epigenetic biomarkers and clinical factors in
upper tract urothelial carcinoma. Epigenomics. 7:733–744. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Epstein JI, Amin MB and Reuter VR: The
World Health Organization/International Society of Urological
Pathology consensus classification of urothelial (transitional
cell) neoplasms of the urinary bladder. Bladder Consensus
Conference Committee. Am J Surg Pathol. 22:1435–1448. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Casadio V, Molinari C, Calistri D, Tebaldi
M, Gunelli R, Serra L, Falcini F, Zingaretti C, Silvestrini R,
Amadori D and Zoli W: DNA methylation profiles as predictors of
recurrence in non muscle invasive bladder cancer: An MS-MLPA
approach. J Exp Clin Cancer Res. 32:942013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Catto JW, Azzouzi AR, Rehman I, Feeley KM,
Cross SS, Amira N, Fromont G, Sibony M, Cussenot O, Meuth M and
Hamdy FC: Promoter hypermethylation is associated with tumor
location, stage and subsequent progression in transitional cell
carcinoma. J Clin Oncol. 23:2903–2910. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Maruyama R, Toyooka S, Toyooka KO, Harada
K, Virmani AK, Zöchbauer-Müller S, Farinas AJ, Vakar-Lopez F, Minna
JD, Sagalowsky A, et al: Aberrant promoter methylation profile of
bladder cancer and its relationship to clinicopathological
features. Cancer Res. 61:8659–8663. 2001.PubMed/NCBI
|
|
16
|
Yu J, Zhu T, Wang Z, Zhang H, Qian Z, Xu
H, Gao B, Wang W, Gu L, Meng J, et al: A novel set of DNA
methylation markers in urine sediments for sensitive/specific
detection of bladder cancer. Clin Cancer Res. 13:7296–7304. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Yates DR, Hupertan V, Colin P, Ouzzane A,
Descazeaud A, Long JA, Pignot G, Crouzet S, Rozet F, Neuzillet Y,
et al: Cancer-specific survival after radical nephroureterectomy
for upper urinary tract urothelial carcinoma: Proposal and
multi-institutional validation of a post-operative nomogram. Br J
Cancer. 106:1083–1088. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Seisen T, Colin P, Hupertan V, Yates DR,
Xylinas E, Nison L, Cussenot O, Neuzillet Y, Bensalah K, Novara G,
et al: Postoperative nomogram to predict cancer-specific survival
after radical nephroureterectomy in patients with localised and/or
locally advanced upper tract urothelial carcinoma without
metastasis. BJU Int. 114:733–740. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Rouprêt M, Hupertan V, Seisen T, Colin P,
Xylinas E, Yates DR, Fajkovic H, Lotan Y, Raman JD, Zigeuner R, et
al: Prediction of cancer specific survival after radical
nephroureterectomy for upper tract urothelial carcinoma:
Development of an optimized postoperative nomogram using decision
curve analysis. J Urol. 189:1662–1669. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ku JH, Moon KC, Jung JH, Jeong SH, Kwak C
and Kim HH: External validation of an online nomogram in patients
undergoing radical nephroureterectomy for upper urinary tract
urothelial carcinoma. Br J Cancer. 109:1130–1136. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Hagiwara M, Kikuchi E, Tanaka N, Matsumoto
K, Ide H, Miyajima A, Masuda T, Nakamura S and Oya M: Impact of
smoking status on bladder tumor recurrence after radical
nephroureterectomy for upper tract urothelial carcinoma. J Urol.
189:2062–2068. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kusuda Y, Miyake H, Terakawa T, Kondo Y,
Miura T and Fujisawa M: Gender as a significant predictor of
intravesical recurrence in patients with urothelial carcinoma of
the upper urinary tract following nephroureterectomy. Urol Oncol.
31:899–903. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Xylinas E, Colin P, Audenet F, Phe V,
Cormier L, Cussenot O, Houlgatte A, Karsenty G, Bruyère F, Polguer
T, et al: Intravesical recurrence after radical nephroureterectomy
for upper tract urothelial carcinomas: Predictors and impact on
subsequent oncological outcomes from a national multicenter study.
World J Urol. 31:61–68. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Hamidi T, Singh AK and Chen T: Genetic
alterations of DNA methylation machinery in human diseases.
Epigenomics. 7:247–265. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Costa VL, Henrique R, Danielsen SA,
Duarte-Pereira S, Eknaes M, Skotheim RI, Rodrigues A, Magalhães JS,
Oliveira J, Lothe RA, et al: Three epigenetic biomarkers, GDF15,
TMEFF2 and VIM, accurately predict bladder cancer from DNA-based
analyses of urine samples. Clin Cancer Res. 16:5842–5851. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Besaratinia A, Cockburn M and Tommasi S:
Alterations of DNA methylome in human bladder cancer. Epigenetics.
8:1013–1022. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Kandimalla R, van Tilborg AA and Zwarthoff
EC: DNA methylation-based biomarkers in bladder cancer. Nat Rev
Urol. 10:327–335. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Habuchi T, Takahashi R, Yamada H, Kakehi
Y, Sugiyama T and Yoshida O: Metachronous multifocal development of
urothelial cancers by intraluminal seeding. Lancet. 342:1087–1088.
1993. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Habuchi T: Origin of multifocal carcinomas
of the bladder and upper urinary tract: Molecular analysis and
clinical implications. Int J Urol. 12:709–716. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Huo Y, Zheng Z, Chen Y, Wang Q, Zhang Z
and Deng H: Downregulation of vimentin expression increased drug
resistance in ovarian cancer cells. Oncotarget. 7:45876–45888.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Monteiro-Reis S, Leca L, Almeida M,
Antunes L, Monteiro P, Dias PC, Morais A, Oliveira J, Henrique R
and Jerónimo C: Accurate detection of upper tract urothelial
carcinoma in tissue and urine by means of quantitative GDF15,
TMEFF2 and VIM promoter methylation. Eur J Cancer. 50:226–233.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Nowakowska M, Matysiak-Burzynska Z,
Kowalska K, Pluciennik E, Dominska K and Piastowska-Ciesielska AW:
Angiotensin II promotes endometrial cancer cell survival. Oncol
Rep. 36:1101–1110. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Wen L, Li J, Guo H, Liu X, Zheng S, Zhang
D, Zhu W, Qu J, Guo L, Du D, et al: Genome-scale detection of
hypermethylated CpG islands in circulating cell-free DNA of
hepatocellular carcinoma patients. Cell Res. 25:1250–1264. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Zuo J, Wen J, Lei M, Wen M, Li S, Lv X,
Luo Z and Wen G: Hypoxia promotes the invasion and metastasis of
laryngeal cancer cells via EMT. Med Oncol. 33:152016. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Miranda E, Bianchi P, Destro A, Morenghi
E, Malesci A, Santoro A, Laghi L and Roncalli M: Genetic and
epigenetic alterations in primary colorectal cancers and related
lymph node and liver metastases. Cancer. 119:266–276. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Kim SA, Inamura K, Yamauchi M, Nishihara
R, Mima K, Sukawa Y, Li T, Yasunari M, Morikawa T, Fitzgerald KC,
et al: Loss of CDH1 (E-cadherin) expression is associated with
infiltrative tumour growth and lymph node metastasis. Br J Cancer.
114:199–206. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Huang R, Ding P and Yang F:
Clinicopathological significance and potential drug target of CDH1
in breast cancer: A meta-analysis and literature review. Drug Des
Devel Ther. 9:5277–5285. 2015.PubMed/NCBI
|
|
38
|
Abe T, Shinohara N, Harabayashi T, Sazawa
A, Akino T, Ishikawa S, Kubota K, Matsuno Y, Osawa T, Shibata T, et
al: Pathological characteristics and clinical course of bladder
tumour developing after nephroureterectomy. BJU Int. 105:1102–1106.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Tanaka N, Kikuchi E, Kanao K, Matsumoto K,
Shirotake S, Kobayashi H, Miyazaki Y, Ide H, Obata J, Hoshino K, et
al: Independent predictors for bladder outcomes after treatment of
intravesical recurrence following radical nephroureterectomy in
patients with primary upper tract urothelial carcinoma. Ann Surg
Oncol. 21:3151–3158. 2014. View Article : Google Scholar : PubMed/NCBI
|
